Article Information
History
- October 1, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Diana H. Quan1,2,
- Claudio Counoupas1,2,
- Gayathri Nagalingam1,2,
- Rachel Pinto1,2,
- Nikolai Petrovsky3,
- Warwick J. Britton1,2 and
- James A. Triccas1,2,4,*
- 1Discipline of Infectious Diseases and Immunology, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, 2006, NSW, Australia
- 2Tuberculosis Research Program, Centenary Institute, The University of Sydney, 2006, NSW, Australia
- 3Department of Endocrinology, Flinders University, Adelaide, Australia and Vaxine Pty Ltd, Adelaide 5042, Australia
- 4Department of Clinical Immunology, Royal Prince Alfred Hospital, Camperdown, 2050, NSW, Australia
- 5Charles Perkins Centre and Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, 2006, NSW, Australia
- ↵*Correspondence: Professor J A Triccas Email: jamie.triccas{at}sydney.edu.au
Posted October 01, 2020.
Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity
